1. Rapid progression of prostate cancer in men with a BRCA2 mutation.
- Author
-
Narod, SA, Neuhausen, S, Vichodez, G, Armel, S, Lynch, HT, Ghadirian, P, Cummings, S, Olopade, O, Stoppa-Lyonnet, D, Couch, F, Wagner, T, Warner, E, Foulkes, WD, Saal, H, Weitzel, J, Tulman, A, Poll, A, Nam, R, Sun, P, Hereditary Breast Cancer Study Group, Danquah, Jessica, Domchek, Susan, Tung, Nadine, Ainsworth, Peter, Horsman, Douglas, Kim-Sing, Charmaine, Maugard, Christine, Eisen, Andrea, Daly, Mary, McKinnon, Wendy, Wood, Marie, Isaacs, Claudine, Gilchrist, Dawna, Karlan, Beth, Nedelcu, Raluca, Meschino, Wendy, Garber, Judy, Pasini, Barbara, Manoukian, Siranoush, and Bellati, Christina
- Subjects
Hereditary Breast Cancer Study Group ,Humans ,Prostatic Neoplasms ,Disease Progression ,Genetic Predisposition to Disease ,Heterozygote ,Mutation ,Genes ,BRCA1 ,Genes ,BRCA2 ,Adult ,Aged ,Aged ,80 and over ,Middle Aged ,Male ,prostate cancer ,BRCA1 ,BRCA2 ,Genes ,and over ,Oncology and Carcinogenesis ,Public Health and Health Services ,Oncology & Carcinogenesis - Abstract
Men with BRCA2 mutations have been found to be at increased risk of developing prostate cancer. There is a recent report that BRCA2 carriers with prostate cancer have poorer survival than noncarrier prostate cancer patients. In this study, we compared survival of men with a BRCA2 mutation and prostate cancer with that of men with a BRCA1 mutation and prostate cancer. We obtained the age at diagnosis, age at death or current age from 182 men with prostate cancer from families with a BRCA2 mutation and from 119 men with prostate cancer from families with a BRCA1 mutation. The median survival from diagnosis was 4.0 years for men with a BRCA2 mutation vs 8.0 years for men with a BRCA1 mutation, and the difference was highly significant (P
- Published
- 2008